LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "pepi" as a keyword



Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index

Sign Up to like & get
recommendations! Published in 2020 at "European Radiology"

DOI: 10.1007/s00330-020-07058-3

Abstract: To investigate whether contralateral parenchymal enhancement (CPE) on MRI during neoadjuvant endocrine therapy (NET) is associated with the preoperative endocrine prognostic index (PEPI) of ER+/HER2− breast cancer. This retrospective observational cohort study included 40 unilateral… read more here.

Keywords: breast; pepi; pathology; endocrine ... See more keywords

The β-globin Replicator greatly enhances the potential of S/MAR based episomal vectors for gene transfer into human haematopoietic progenitor cells

Sign Up to like & get
recommendations! Published in 2017 at "Scientific Reports"

DOI: 10.1038/srep40673

Abstract: Specific human chromosomal elements enhance the performance of episomal gene-transfer vectors. S/MAR-based episomal vector pEPI-eGFP transfects CD34+ haematopoietic cells, but only transiently. To address this issue we reinforced (1) transgene transcription by replacing the CMV… read more here.

Keywords: vector; progenitor cells; pepi; sffv ... See more keywords

Abstract CT144: Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2- breast cancer

Sign Up to like & get
recommendations! Published in 2023 at "Cancer Research"

DOI: 10.1158/1538-7445.am2023-ct144

Abstract: Background: Most estrogen receptor alpha positive (ER+) breast cancers (BCs) express androgen receptor (AR) protein, but its function is unclear. High AR relative to ER is associated with endocrine resistance. This randomized phase II trial… read more here.

Keywords: pepi; arm; surgery; phase trial ... See more keywords

Neoadjuvant biomarker trial of pepinemab to enhance nivolumab or ipilimumab activity in resectable head and neck cancer.

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2025.43.16_suppl.103

Abstract: 103 Background: Neoadjuvant treatment with immune checkpoint blockade (ICB) improves clinical benefit in patients with multiple types of cancers. Window of opportunity studies permit integrated assessments of safety and efficacy, including biomarker assessments of treatment… read more here.

Keywords: hpv; pepinemab; pepi; tumor ... See more keywords